Objectives Assessing efficacy, safety. Methods adult patients on stable originator infliximab were randomised to continued INX or switch to CT-P13 treatment in the main study 1. All extension participants received CT-P The primary endpoint was disease worsening, analysed with logistic regression, adjusted for diagnosis and treatment duration.
Results patients entered the extension trial. Disease worsening in the study arms Per Protocol Set, PPS and in each diagnosis explorative analyses are shown table 1. Generic disease variables, disease specific composite measures, trough drug levels, anti-drug antibodies and reported adverse events were comparable between groups data not shown. LancetJun 10; β Disclosure of Interest G. Sexton: None declared, I.
Olsen Consultant for: Pfizer, N. Lorentzen: None declared, E. You will be able to get a quick price and instant permission to reuse the content in many different ways. Skip to main content. Log in via OpenAthens. Log in using your username and password For personal accounts OR managers of institutional accounts. Forgot your log in details? Register a new account? Forgot your user name or password? Search for this keyword. Advanced search. Log in via Institution.
Email alerts. Article Text. Article menu. Goll 1 , K. Sexton 1 , I. Olsen 1 , N. Bolstad 3 , M. Lorentzen 4 , E. Haavardsholm 1 , C. Jahnsen 2 , T. View this table: View inline View popup. Abstract AB β Table 1. Statistics from Altmetric. Read the full text or download the PDF:. Log in.
